Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Revenue (2016 - 2025)

Marker Therapeutics has reported Revenue over the past 9 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Revenue fell 51.0% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 52.21% year-over-year, with the annual reading at $3.5 million for FY2025, 46.19% down from the prior year.
  • Revenue was $1.1 million for Q4 2025 at Marker Therapeutics, down from $1.2 million in the prior quarter.
  • Over five years, Revenue peaked at $2.5 million in Q1 2023 and troughed at -$503005.0 in Q2 2023.
  • The 4-year median for Revenue is $1.0 million (2022), against an average of $1.1 million.
  • Year-over-year, Revenue tumbled 163.63% in 2023 and then soared 647.66% in 2024.
  • A 4-year view of Revenue shows it stood at $759143.0 in 2022, then surged by 39.17% to $1.1 million in 2023, then soared by 113.13% to $2.3 million in 2024, then plummeted by 51.0% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Revenue are $1.1 million (Q4 2025), $1.2 million (Q3 2025), and $861184.0 (Q2 2025).